Female Sexual Dysfunction (FSD) represents a significant unmet medical need in a large population and therefore a substantial opportunity for drug developers. However, clinical studies in indications such as Female Sexual Interest/Arousal Disorder present substantial challenges. These include evolving terminology in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), complex diagnostic criteria, common comorbidities, debate about appropriate endpoints and complexity in site selection given treatment by OB/GYNs, psychologists, psychiatrists, sex therapists and pelvic physical therapists. Relationships with Key Opinion Leaders (KOLs) in FSD are critical. Health Decisions has the expertise and KOL and site relationships required to conduct successful FSD studies. Download this fact sheet to learn more about Health Decisions’ capabilities for studies in this challenging area.